PD173074

Licensed by Pfizer Catalog No.S1264

Molecular Weight(MW): 523.67

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Cited by 27 Publications

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Discov, 2013, 3(6):636-47

PubMed: 23558953 ( click the link to review the publication )

Gut, 2014, 63(12):1932-42

PubMed: 24658599 ( click the link to review the publication )

Blood, 2014, 123(10):1516-24

PubMed: 24408322 ( click the link to review the publication )

Hepatology, 2014, 59(4):1427-34

PubMed: 24122810 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(12):1736-44

PubMed: 26473643 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(4):962-973

PubMed: 27535980 ( click the link to review the publication )

Cancer Res, 2016, 10.1158/0008-5472.CAN-16-0058

PubMed: 27231203 ( click the link to review the publication )

Cancer Res, 2016, 76(22):6471-6482

PubMed: 27671675 ( click the link to review the publication )

Biomaterials, 2016, 78:115-28

PubMed: 26691234 ( click the link to review the publication )

Stem Cell Reports, 2018, 10(4):1308-1323

PubMed: 29526737 ( click the link to review the publication )
J Neurosci, 2016, 36(16):4534-48

PubMed: 27098696 ( click the link to review the publication )

PLoS Genet, 2012, 8(2):e1002500

PubMed: 22383889 ( click the link to review the publication )

Osteoarthritis Cartilage, 2018, 26(12):1733-1743

PubMed: 30201491 ( click the link to review the publication )

Mol Oncol, 2018, 10.1002/1878-0261.12422

PubMed: 30537101 ( click the link to review the publication )

Mol Cell Proteomics, 2012, 11(9):745-57

PubMed: 22700489 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(12):1585-96

PubMed: 24092775 ( click the link to review the publication )

J Cell Sci, 2014, 127(23):5079-92

PubMed: ( click the link to review the publication )

Am J Physiol Endocrinol Metab, 2017, ajpendo.00328.2016

PubMed: 28174179 ( click the link to review the publication )

Breast Cancer Res Tr, 2014, 143(3):435-46

PubMed: 24398778 ( click the link to review the publication )

Clin Exp Metastasis, 2012, 30(4):507-20

PubMed: 23212305 ( click the link to review the publication )

Exp Cell Res, 2015, 332(2):223-35

PubMed: 25704758 ( click the link to review the publication )
PLoS One, 2014, 9(4):e95434

PubMed: 24752320 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56735

PubMed: 23468877 ( click the link to review the publication )

Celon Pharma Inc, 2013, Paulina Grygielewicz

PubMed: ( click the link to review the publication )

7 Customer Reviews

The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

Science 2011 331(6019), 912-6. PD173074 purchased from Selleck.

Inhibition of FGFR signaling pathway by FGFR inhibitor PD173074 in mouse xenograft tumors. Bladder cancer SW780 cells were implanted in mice and treated with PD173074 after tumor formation as shown in B. Protein lysates of tumor tissues were prepared and immunoblotted with antibodies against phospho-ERK1/2, pan-ERK1/2, and γ-tubulin.

Cancer Discov 2013 3(6), 636-47. PD173074 purchased from Selleck.
FGFR inhibitors block signaling in FGFR2-fusion-expressing cells. Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIH3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 uM BGJ398, and 0.2 and 1 uM PD173074 were immunoblotted with the relevant antibodies. β-Actin was used as a loading control.

Hepatology 2014 59(4) ,1427-34. PD173074 purchased from Selleck.

The level of p-FRS2 was examined in the uterine sections of Msx1f/fMsx2f/f (upper panel) and Msx1d/dMsx2d/d (lower panel) mice on day 4 of pregnancy by immunohistochemistry. Magnification: a and d: 10 x, b and e: 20 x, c and f: 40x. FGFR-specific inhibitor PD173074 was applied to one uterine horn of Msx1d/dMsx2d/d (n = 3) mice on day 3 of pregnancy. The other horn served as vehicle-treated control. Uterine horns were collected on day 4 morning and sections were subjected to immunohistochemistry to detect p-FRS2, Ki67, and Muc-1.

PLoS Genet 2012 8(2), e1002500. PD173074 purchased from Selleck.
Cells were incubated with DMSO control, 10 uM TGFBR inhibitor or 10 uM FGFR inhibitor PD173074 for 1 h. Cells were fixed, labeled with anti-GM130 (red) and analyzed by confocal microscopy. Images were analyzed using Image J (n = 3 experiments, >100 cells per condition). Scale bars, 10 uM.

J Cell Sci 2014 10.1242/jcs.159608. PD173074 purchased from Selleck.

Effects of antagonists for RAGE (FPS-ZM), TLR-4 (TAK-242) and FGFR1 (PD and BGJ) on the S100B-induced alterations in glucose metabolism in L6 cells treated for 6 h. (A) Effects of FPS-ZM, (B) TAK-242 and (C) PD and BGJ on the S100B inhibition of glucose consumption.

Am J Physiol Endocrinol Metab, 2017, 312(6):E471-E481. PD173074 purchased from Selleck.
Effect of select kinase inhibitors on DF508-CFTR maturation analyzed by immunoblotting. 293MSR-GT cells stably expressing DF508-CFTR were treated with 15 uM kinase inhibitors or 0.3% DMSO (vehicle control), as indicated, grown at 37 ℃ for 48 h, and the appearance of the mature protein, band C, monitored by immunoblotting with anti-CFTR antibodies. Band B represents the immature protein. DMSO represents vehicle- alone control, 27℃ represents temperature rescue of F508-CFTR at 27℃, 37℃ represents untreated DF508-CFTR control, and WT represents WT-CFTR. Top panels depict the anti-CFTR immunoblot and bottom panels depict actin (loading) control. ** represents cellular toxicity.

Biochem Bioph Res Co 2012 11(9), 745-57. PD173074 purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description

PD173074 is a potent FGFR1 inhibitor with IC50 of ~25 nM and also inhibits VEGFR2 with IC50 of 100-200 nM in cell-free assays, ~1000-fold selective for FGFR1 than PDGFR and c-Src.

Targets

FGFR1 ^[1] (Cell-free assay)	VEGFR2 ^[1] (Cell-free assay)
~25 nM	100 nM-200 nM

In vitro

PD173074 is an ATP-competitive inhibitor of FGFR1 with K_i of ~40 nM. PD173074 is also an effective inhibitor of VEGFR2. Compared to FGFR1, PD173074 weakly inhibits the activities of Src, InsR, EGFR, PDGFR, MEK, and PKC with 1000-fold or greater IC50 values. PD173074 inhibits autophosphorylation of FGFR1 and VEGFR2 in a dose-dependent manner with IC50 of 1-5 nM and 100-200 nM, respectively. ^[1] PD173074 inhibits FGF-2 promotion of granule neuron survival in a dose-dependent manner with IC50 of 12 nM, exhibiting 1,000-fold greater potency than that of SU 5402. ^[2] PD173074 specifically inhibits FGF-2-mediated effects on proliferation, differentiation, and MAPK activation in oligodendrocyte (OL) lineage cells. ^[3] PD173074 is active against the WT receptor and FGFR3 mutations in multiple myeloma (MM) cell lines. PD173074 also potently inhibits autophosphorylation of FGFR3 in a dose-dependent manner with IC50 of ~5 nM. PD173074 treatment potently reduces viability of FGFR3-expressing KMS11 and KMS18 cells with IC50 of <20 nM. Inhibition of aFGF-stimulated MM cell growth by PD173074 is highly correlated with the expression of FGFR3. PD173074 treatment completely abolishes NIH 3T3 transformation mediated by Y373C FGFR3 but not by Ras V12, demonstrating that PD173074 specifically targets FGFR3-mediated cell transformation and lacks nonspecific cytotoxic effect. PD173074 also induces functional maturation of KMS11 and KMS18 cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
NCI-H1581	M4fpSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMEGyNlUh\|ryP	MVXTRW5ITVJ?
KG-1	M1Ltd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMEWxNlkh\|ryP	NWjiZ206W0GQR1XS
MFM-223	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4WzSWlEPTB;MD6yNVU4PiEQvF2=	MY\TRW5ITVJ?
EoL-1-cell	MormS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLqZ5FUUUN3ME2wMlMzQTh2IN88US=>	MnTnV2FPT0WU
ECC10	NFe2OWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTQdZV2UUN3ME2wMlM{QDl6IN88US=>	NYDUU5NwW0GQR1XS
H-EMC-SS	NGHxR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTQTWM2OD1yLkO0O\|E2KM7:TR?=	MkHtV2FPT0WU
AN3-CA	NHTadYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rNPGlEPTB;MD60NFE{OyEQvF2=	NH\XPFdUSU6JRWK=
HuO-3N1	M4TKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\hSVB{UUN3ME2wMlU1PjV\|IN88US=>	M3vuUnNCVkeHUh?=
RT-112	M4X4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jDcmlEPTB;MD61OFcxOSEQvF2=	NYO0cGo1W0GQR1XS
NEC8	NWfOTXRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TuT2lEPTB;MD61OlI5QSEQvF2=	NEOyTYFUSU6JRWK=
D-263MG	MkHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEHodldKSzVyPUCuO\|EyPTlizszN	NWn1[4VQW0GQR1XS
SW962	Mnq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr1cG1rUUN3ME2wMlc5QTh6IN88US=>	MYTTRW5ITVJ?
BV-173	MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPTfIdKSzVyPUCuPFQ3OjNizszN	MX;TRW5ITVJ?
MFE-280	M{PUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrjTWM2OD1yLki1PFczKM7:TR?=	NGD2fJVUSU6JRWK=
HuH-7	NIjOZ45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{SweWlEPTB;MT6yOFQ3PCEQvF2=	MUHTRW5ITVJ?
RS4-11	NFPMd3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIX5OYlKSzVyPUGuN\|M5QDZizszN	MX\TRW5ITVJ?
DMS-114	MnnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwM{[3N\|ch\|ryP	NWfrbYdzW0GQR1XS
MSTO-211H	M4fwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwNEezO\|gh\|ryP	MYjTRW5ITVJ?
DU-145	NI\BSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXz3XIJJUUN3ME2xMlU5OjF5IN88US=>	Mk\BV2FPT0WU
A172	MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTFwN{CzOVUh\|ryP	MWrTRW5ITVJ?
SBC-1	M2LmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTJwMEm0JO69VQ>?	MWDTRW5ITVJ?
H9	M2Lue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnNTlhMUUN3ME2yMlE1OzB4IN88US=>	MX\TRW5ITVJ?
NCI-SNU-1	NVfSVINLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHocm9UUUN3ME2yMlE5Ozl2IN88US=>	NWH0dpFPW0GQR1XS
NCI-H720	NFvIZoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTJwMkGyPFMh\|ryP	NFT5T3hUSU6JRWK=
HCC2218	NGjr[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXKTWM2OD1{LkO3PVM6KM7:TR?=	M{PlfXNCVkeHUh?=
G-401	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTJwNEexPFkh\|ryP	M2f6VnNCVkeHUh?=
MPP-89	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4jHXGlEPTB;Mj60PFM3PCEQvF2=	NHXFbmRUSU6JRWK=
697	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX21Vmk6UUN3ME2yMlY2OzNzIN88US=>	MXLTRW5ITVJ?
KARPAS-45	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTJwN{C3OFch\|ryP	NXnDUHhDW0GQR1XS
MG-63	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTJwOUSyOlIh\|ryP	MV\TRW5ITVJ?
NTERA-S-cl-D1	NUTqcnpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H0[GlEPTB;Mz6wN\|Q4OiEQvF2=	M4ezVnNCVkeHUh?=
G-402	NXjSeXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTZOZFnUUN3ME2zMlEzPzJ5IN88US=>	M4PCOnNCVkeHUh?=
NKM-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTNwMUO1OlQh\|ryP	M3f2UnNCVkeHUh?=
RH-18	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1\KZ2lEPTB;Mz6xPVU6QCEQvF2=	M1XZS3NCVkeHUh?=
NCI-H1092	NIjDSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\kTWM2OD1\|LkG5Olkh\|ryP	NH3pPWFUSU6JRWK=
RPMI-8226	M3PVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;ObmlEPTB;Mz6yN\|Q1PyEQvF2=	NVj5NZlnW0GQR1XS
GAMG	M4ezW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrjc2J5UUN3ME2zMlQ3PTd4IN88US=>	NVrMR\|drW0GQR1XS
HH	NUHZTo1wT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTNwNEe2O\|Yh\|ryP	MoHyV2FPT0WU
RO82-W-1	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUXyT4lDUUN3ME2zMlQ6QDV3IN88US=>	M4rFUnNCVkeHUh?=
CCRF-CEM	NF7STYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\ueIp[UUN3ME2zMlUxPDh6IN88US=>	NYq2NoN[W0GQR1XS
NBsusSR	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfaTWM2OD1\|Lk[zPVY6KM7:TR?=	NID3dphUSU6JRWK=
CHL-1	NH7wXHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rkUWlEPTB;Mz62OVc6QSEQvF2=	M2DaXHNCVkeHUh?=
LK-2	NV[3fIdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3v1[WlEPTB;Mz62O\|E{OyEQvF2=	M1[3d3NCVkeHUh?=
Hs-578-T	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEnKSHVKSzVyPUOuOlc5PzNizszN	MWnTRW5ITVJ?
CTB-1	M{XTPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnIeGtKSzVyPUOuPFAxPTFizszN	NETCSGZUSU6JRWK=
ES5	MnnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVz5NYhkUUN3ME2zMlg{PjN5IN88US=>	NES5PVBUSU6JRWK=
A204	M{n3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTNwOUKwO\|Uh\|ryP	MXXTRW5ITVJ?
SW780	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTNwOUKyOFUh\|ryP	M3XuUXNCVkeHUh?=
EW-3	M{LEXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDtTWM2OD1\|Lkm4PVI{KM7:TR?=	MlLVV2FPT0WU
A704	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTRwMki3NlMh\|ryP	M3\Ie3NCVkeHUh?=
LU-139	NInufodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTRwM{G1N\|Qh\|ryP	MUDTRW5ITVJ?
CAL-72	NXHnRlJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7GTWM2OD12LkSxO\|Q3KM7:TR?=	MnXWV2FPT0WU
D-336MG	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1Hoc2lEPTB;ND60OlgyPyEQvF2=	Mn;qV2FPT0WU
LAMA-84	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWfxXHgyUUN3ME20MlU{OzFizszN	NWW1N4U{W0GQR1XS
GI-ME-N	NH3n[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUnJR\|UxRTRwNUS4NUDPxE1?	MUDTRW5ITVJ?
KM-H2	Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fNZmlEPTB;ND61OVIzOiEQvF2=	M2\UXnNCVkeHUh?=
NCI-H209	M3L6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1HKfGlEPTB;ND61PFI5OyEQvF2=	NUW0bWVEW0GQR1XS
IGROV-1	NHuxNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTRwOEexOlgh\|ryP	MXvTRW5ITVJ?
L-363	M{HEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrsWHlHUUN3ME20Mlk3PjZ3IN88US=>	M1vCNXNCVkeHUh?=
SK-MEL-3	NYTWfJc2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTVwMkSwOkDPxE1?	MnXNV2FPT0WU
HuO9	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTVwM{i4OFMh\|ryP	NW\hNWRMW0GQR1XS
NOS-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTVwN{K5Nlch\|ryP	MWDTRW5ITVJ?
NCI-H1770	NGfZcnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTVwOUWwN\|Ih\|ryP	NWm5[5VwW0GQR1XS
SF126	Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoKyTWM2OD14LkKxOFA3KM7:TR?=	MlPZV2FPT0WU
ML-2	M1jId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWTBNWlwUUN3ME22MlI1QTd5IN88US=>	M37wdXNCVkeHUh?=
CHP-134	NILKUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXO4dnRjUUN3ME22MlI2OTh{IN88US=>	MYPTRW5ITVJ?
NCI-H1355	NV3sNmxoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPOdFV7UUN3ME22MlQyPzN\|IN88US=>	MUfTRW5ITVJ?
TE-12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HtR2lEPTB;Nj63NlY4OSEQvF2=	M3\MXXNCVkeHUh?=
A4-Fuk	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTZwN{OxOFIh\|ryP	M2TGb3NCVkeHUh?=
MV-4-11	NUK4VZh2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTZwN{[2NlYh\|ryP	NUPSTmV{W0GQR1XS
SK-UT-1	M3faVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTZwOUG3PFQh\|ryP	MUfTRW5ITVJ?
J-RT3-T3-5	NYnUNHNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TnbGlEPTB;Nz6wO\|c3PCEQvF2=	MoDhV2FPT0WU
ME-180	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33rbWlEPTB;Nz6xNFQxPCEQvF2=	MkX2V2FPT0WU
SK-MEL-28	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrhTWM2OD15LkO3PFE6KM7:TR?=	M3v4TnNCVkeHUh?=
HAL-01	MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWT5[HR{UUN3ME23MlQ5OzRzIN88US=>	NFzBOZhUSU6JRWK=
ES8	M2\QXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHYe2RKSzVyPUeuOlk3OjZizszN	M1niSHNCVkeHUh?=
DB	Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDIUmtKSzVyPUiuNVE2ODRizszN	NVnvb2NlW0GQR1XS
SK-NEP-1	NXPk[FRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TP[GlEPTB;OD60PFE1QSEQvF2=	MWnTRW5ITVJ?
COR-L88	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG2foRKSzVyPUiuOVA6QDFizszN	M1jWc3NCVkeHUh?=
LB1047-RCC	NEXBUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnCbWdKSzVyPUiuOVIzOTJizszN	NH[5RnVUSU6JRWK=
NCI-H520	NHXoOlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTHWYZKSzVyPUiuOlIyPTdizszN	M4Do[nNCVkeHUh?=
SW954	M3[xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\zTWM2OD16Lk[5O\|g3KM7:TR?=	NU\0dlZ2W0GQR1XS
TE-6	MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XJNWlEPTB;OD63OVE1OyEQvF2=	M{OyenNCVkeHUh?=
D-283MED	NU\vSoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7iR5Z3UUN3ME25MlA3PTN2IN88US=>	NVeye45jW0GQR1XS
DBTRG-05MG	MoDNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvhTWM2OD17LkC5OlA4KM7:TR?=	NHzNS3NUSU6JRWK=
NCI-H446	NX3oPJBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLPdJY{UUN3ME25MlI6PTJ4IN88US=>	NFf0RZZUSU6JRWK=
HOS	NVL0fWE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrUTY1{UUN3ME25MlM2OTN2IN88US=>	NHPlNVBUSU6JRWK=
ES4	NYHoVGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\yfZpkUUN3ME25MlUxPTl3IN88US=>	NHnGbWFUSU6JRWK=
EW-13	NVnGPFNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jiWGlEPTB;OT64PVA2PSEQvF2=	MnW3V2FPT0WU
IST-MES1	NVvwUVdYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7QTWM2OD17Lkm0OVM1KM7:TR?=	MXHTRW5ITVJ?
CAS-1	M3:wb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3DTWM2OD17Lkm3OlU6KM7:TR?=	M3PyO3NCVkeHUh?=
EM-2	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTFyLkGzPVMh\|ryP	MmDJV2FPT0WU
SW948	NHfiWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrtUXlrUUN3ME2xNE4yQDh{IN88US=>	MUPTRW5ITVJ?
OAW-42	NEjCfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\NWIc{UUN3ME2xNE42OjZ5IN88US=>	MmjsV2FPT0WU
BE-13	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfQTWM2OD1zMD62OVc3KM7:TR?=	MX\TRW5ITVJ?
KU812	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzmZYtKSzVyPUGwMlc{QTFizszN	MWLTRW5ITVJ?
SK-MEL-30	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXvUnhKSzVyPUGwMlg6ODFizszN	M1fVc3NCVkeHUh?=
A2780	Moe3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnf2TWM2OD1zMT6wN\|A5KM7:TR?=	NIO1cm1USU6JRWK=
TGBC24TKB	NY[5c\|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFy3[pdKSzVyPUGxMlA4OzdizszN	NHTYZ5NUSU6JRWK=
GOTO	M3O2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjTTWM2OD1zMT6yNFg1KM7:TR?=	NInLTZFUSU6JRWK=
NCI-H526	MoGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTFzLkO4N\|ch\|ryP	M4HQUnNCVkeHUh?=
BHT-101	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTFzLkS0OVYh\|ryP	NGK1eoFUSU6JRWK=
NCI-H1155	NVPNdYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2na[2lEPTB;MUGuOFk1PyEQvF2=	MoDLV2FPT0WU
MCF7	NHnze5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXsTWM2OD1zMT62NVY4KM7:TR?=	NHu5b4xUSU6JRWK=
MKN45	MnvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWrjWmtwUUN3ME2xNU44QTl\|IN88US=>	M3mxNXNCVkeHUh?=
MOLT-16	M{TFUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PRSmlEPTB;MUGuPVY6OiEQvF2=	M2XmVnNCVkeHUh?=
YH-13	M1jVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTF{LkCzOFYh\|ryP	MnvvV2FPT0WU
P12-ICHIKAWA	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3lTJVKSzVyPUGyMlM5PDVizszN	NHXHOVNUSU6JRWK=
GR-ST	NYrl[ZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTuTWM2OD1zMj61Nlk2KM7:TR?=	M1z3WXNCVkeHUh?=
CAKI-1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3X2TGlEPTB;MUKuO\|kyKM7:TR?=	MWXTRW5ITVJ?
LXF-289	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnKwTWM2OD1zMz6wPFM2KM7:TR?=	NW\VVIlKW0GQR1XS
MHH-PREB-1	NFjUbYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7NTWM2OD1zMz6yO\|A1KM7:TR?=	MWPTRW5ITVJ?
EW-16	NF;wRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTF\|LkOxPFch\|ryP	MmPQV2FPT0WU
NCI-H82	NELNfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn[5TWM2OD1zMz60NVk2KM7:TR?=	M1PRXHNCVkeHUh?=
MMAC-SF	NGLpS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmTiTWM2OD1zMz60OVQ4KM7:TR?=	MWrTRW5ITVJ?
COLO-684	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jpU2lEPTB;MUOuOVMyQCEQvF2=	NFPYSWNUSU6JRWK=
QIMR-WIL	M2\MdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGniWGJKSzVyPUGzMlgyODlizszN	MkjUV2FPT0WU
NB69	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfjWHN4UUN3ME2xN{46QDZ6IN88US=>	NVXQZlJqW0GQR1XS
NCI-H2291	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTF2LkS0OVMh\|ryP	NELHblhUSU6JRWK=
MKN7	NGPYUZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3GTWM2OD1zND62Olc3KM7:TR?=	MV3TRW5ITVJ?
HDLM-2	M2\GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXLJR\|UxRTF3LkGyPFYh\|ryP	NV\DVmdFW0GQR1XS
A253	NXzKbHJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NICwWVVKSzVyPUG1MlM5PjlizszN	NF;SXVJUSU6JRWK=
SK-LU-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TMeWlEPTB;MUWuPVA6PCEQvF2=	MnLjV2FPT0WU
MEG-01	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3:3[2lEPTB;MUWuPVExPyEQvF2=	Moi2V2FPT0WU
SK-N-DZ	NIeyWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH\JfZpKSzVyPUG1Mlk{PzZizszN	NWDCbJhoW0GQR1XS
H4	NE\ISJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXRUXV{UUN3ME2xOk4xQDhizszN	MV\TRW5ITVJ?
LU-65	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3[5UmlEPTB;MU[uN\|M5PCEQvF2=	MX3TRW5ITVJ?
NCI-H1048	NVnOUmxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTF4LkWxOlUh\|ryP	NGSwZmpUSU6JRWK=
LCLC-97TM1	NWHlVZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnSdmNxUUN3ME2xOk42QDh7IN88US=>	NHLSXZhUSU6JRWK=
CAL-120	NUDtN3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvBUWRKSzVyPUG2Mlk5PzlizszN	NGjtXXJUSU6JRWK=
LU-134-A	M4\oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTF5LkOzPVEh\|ryP	M3:1WHNCVkeHUh?=
SK-MEL-1	NYL1bo9TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTF5LkexNlch\|ryP	MXvTRW5ITVJ?
NCI-H69	NGHrRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTF5LkmzNFch\|ryP	M4nae3NCVkeHUh?=
MC116	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXi0cWg3UUN3ME2xO{46PzVizszN	NXO5RVE2W0GQR1XS
UMC-11	NUP0[5llT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjJTol[UUN3ME2xPE4yPzh6IN88US=>	NXzteHczW0GQR1XS
HCC1395	M3L6Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\vNHFPUUN3ME2xPE41OzBzIN88US=>	M1vNdHNCVkeHUh?=
no-10	M3qxPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NImzdYFKSzVyPUG4MlY{QDhizszN	M3HUUXNCVkeHUh?=
NY	NXfaZZhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mk\JTWM2OD1zOT6wPFA6KM7:TR?=	M4nuVXNCVkeHUh?=
OS-RC-2	NHPTbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXLTWM2OD1zOT6xNlUzKM7:TR?=	NVvie4NiW0GQR1XS
D-423MG	NEO3[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoS0TWM2OD1zOT6zPVUzKM7:TR?=	NV7ENXNHW0GQR1XS
LC-2-ad	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfWTWM2OD1zOT63OlEzKM7:TR?=	NFW5TIhUSU6JRWK=
DU-4475	NHjlcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTF7Lki4OVIh\|ryP	NWrqVJhKW0GQR1XS
YKG-1	MmLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTkTWM2OD1zOT65OlIh\|ryP	M160ZnNCVkeHUh?=
HCC1569	NWPEc2huT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPEUodKSzVyPUKwMlI3OjRizszN	NEjZN5pUSU6JRWK=
TYK-nu	NHnmXo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnSXHk4UUN3ME2yNE4zQDR5IN88US=>	MV;TRW5ITVJ?
DEL	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\jTWlEPTB;MkCuPVgxQCEQvF2=	NI\wVnVUSU6JRWK=
MHH-ES-1	NIXtbXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHOTWM2OD1{MT6zOVk4KM7:TR?=	M3:0cXNCVkeHUh?=
KARPAS-299	NIHhS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHiV2JYUUN3ME2yNU42OjlizszN	MXXTRW5ITVJ?
CTV-1	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1vkdmlEPTB;MkGuOlE4OiEQvF2=	Mnf4V2FPT0WU
NCI-H2452	NUfod\|NIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTJ{Lk[2O\|ch\|ryP	NITvSmhUSU6JRWK=
D-566MG	NH7FRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\kTWM2OD1{Mj63OlAyKM7:TR?=	M3\Ec3NCVkeHUh?=
EFO-27	NVvQNJJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jCdGlEPTB;MkOuNFY2OSEQvF2=	NXS0Z5d4W0GQR1XS
NCI-H596	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvOSXF{UUN3ME2yN{45PTJ5IN88US=>	NXzkPHZMW0GQR1XS
KS-1	NGXQcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2G2WGlEPTB;MkSuNlc2QSEQvF2=	M3PMWXNCVkeHUh?=
8305C	M2n0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2q4ZmlEPTB;MkSuOFA1PSEQvF2=	NGDqSGJUSU6JRWK=
A427	NYTWT2VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVvxXXVDUUN3ME2yOU4xOzJ\|IN88US=>	M1r1enNCVkeHUh?=
COLO-800	NGPUUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJ3LkGwOlEh\|ryP	NVXzNpluW0GQR1XS
SJRH30	NUftXpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTJ3LkO5NFgh\|ryP	NIDydJBUSU6JRWK=
MEL-HO	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHH5O3RKSzVyPUK1MlQ{OTlizszN	NF7jWVRUSU6JRWK=
FTC-133	M1HCfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEOwNXhKSzVyPUK1MlgyQDZizszN	M1vKS3NCVkeHUh?=
SF295	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\JUoVKSzVyPUK2MlI6PiEQvF2=	NIXE[ZZUSU6JRWK=
SW1710	NXjON\|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rxdmlEPTB;Mk[uOFEzOyEQvF2=	NG\xb3JUSU6JRWK=
EFM-19	M3HnO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf0SY5XUUN3ME2yOk45OTR3IN88US=>	M2DMbnNCVkeHUh?=
NB10	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\VXJhKSzVyPUK4MlIzQTdizszN	M2HoXXNCVkeHUh?=
TK10	NGLIUJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXTJR\|UxRTJ6LkKzPVkh\|ryP	NHXXTJFUSU6JRWK=
D-502MG	M1;0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2rJOGlEPTB;MkiuOEDPxE1?	M3jocXNCVkeHUh?=
EW-18	MnjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTsVYlvUUN3ME2yPE41Ozh4IN88US=>	M17mTHNCVkeHUh?=
VMRC-RCZ	NGXtTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLDdZljUUN3ME2yPE46PDFizszN	MkLPV2FPT0WU
Ca9-22	Ml7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUfkVWN6UUN3ME2yPU41PTV5IN88US=>	NVTNfVZNW0GQR1XS
KYSE-70	NXzhOYVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTJ7LkW3PFYh\|ryP	MXXTRW5ITVJ?
A101D	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLXeYh1UUN3ME2yPU43PDd{IN88US=>	NFzmO5pUSU6JRWK=
WM-115	M2PMcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlO5TWM2OD1{OT63OlA4KM7:TR?=	NIDteHJUSU6JRWK=
HCC2157	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIHueGpKSzVyPUK5Mlg5ODdizszN	M2i5cnNCVkeHUh?=
TE-9	M3LIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFT5cJBKSzVyPUK5Mlg5PjVizszN	M{XQR3NCVkeHUh?=
K-562	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXIXINlUUN3ME2zNE4xQTN\|IN88US=>	NXjJVZB6W0GQR1XS
SN12C	M3\uWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnPSXZZUUN3ME2zNE4yPDJ4IN88US=>	MXXTRW5ITVJ?
ESS-1	NXLDS4o5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYD5V29yUUN3ME2zNE41PzV7IN88US=>	MXXTRW5ITVJ?
K5	MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTNyLke2OEDPxE1?	NH7ac3FUSU6JRWK=
J82	NYj0fJJnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlS3TWM2OD1\|MT6wPFk4KM7:TR?=	NETnUHZUSU6JRWK=
HOP-92	MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTNzLkGxNVEh\|ryP	M{XrVHNCVkeHUh?=
NCI-H2228	NGDneXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\sdGlEPTB;M{GuN\|I6PiEQvF2=	MmjiV2FPT0WU
OCI-AML2	NFHHUI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnznTWM2OD1\|MT6zOlEh\|ryP	NHnO[YZUSU6JRWK=
NCI-SNU-5	NFjnO\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrkU4xKSzVyPUOxMlgyOzdizszN	NHvhRXJUSU6JRWK=
A3-KAW	NXnDUJVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HaS2lEPTB;M{GuPVI1OyEQvF2=	NWTRRpB3W0GQR1XS
LCLC-103H	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXUZXVNUUN3ME2zNk4xOTdzIN88US=>	MXnTRW5ITVJ?
KY821	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTN{Lk[4PFQh\|ryP	NHrxfGxUSU6JRWK=
JVM-2	M{HTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3rhWmlEPTB;M{KuPVA4QSEQvF2=	NYr3UmdWW0GQR1XS
Mo-T	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m1fmlEPTB;M{OuNVAxPSEQvF2=	NHTU[WFUSU6JRWK=
IA-LM	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDRdnBRUUN3ME2zN{4zPzVizszN	NH;mXJZUSU6JRWK=
C8166	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWrJR\|UxRTN\|LkOxPVIh\|ryP	MoG3V2FPT0WU
TCCSUP	MmHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIi5flVKSzVyPUOzMlQ{ODdizszN	M3fPUnNCVkeHUh?=
JEG-3	NHywbmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTXT4dKSzVyPUOzMlQ4PjhizszN	MWnTRW5ITVJ?
MS-1	NYXTfnZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnnVYNDUUN3ME2zN{42PTVzIN88US=>	NEHCb\|VUSU6JRWK=
NCI-H1304	NX7neFdMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\PcIk6UUN3ME2zN{42PzJ3IN88US=>	NV[wNos2W0GQR1XS
Ramos-2G6-4C10	NWD1eIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXfMV5hTUUN3ME2zOE4xOzN3IN88US=>	NYO4XmkyW0GQR1XS
MDA-MB-453	M4XWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\tXJJKSzVyPUO0MlY{QTVizszN	NYG3em96W0GQR1XS
KYSE-520	NXrpXJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFHUOnJKSzVyPUO0MlcyQDFizszN	NIXWNm9USU6JRWK=
SW900	MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXrNUmpIUUN3ME2zOE45OTF3IN88US=>	MUDTRW5ITVJ?
HCC2998	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTN3LkG1Nlkh\|ryP	NY[5SpZyW0GQR1XS
A2058	NFSzb4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLzT5VKSzVyPUO1MlYxPjFizszN	Mn35V2FPT0WU
OVCAR-3	NUe0Nm5TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fFdmlEPTB;M{[uNlA1PSEQvF2=	NWK5dpFMW0GQR1XS
MOLT-4	NUPCOYQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTN4LkKyPVQh\|ryP	MmSxV2FPT0WU
CAPAN-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DESmlEPTB;M{[uOFY6QSEQvF2=	M3y0OnNCVkeHUh?=
SCC-9	MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTN5LkSwNlch\|ryP	NWrPVotbW0GQR1XS
SF268	M{LscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn7VTWM2OD1\|OD6zOFM{KM7:TR?=	MWfTRW5ITVJ?
HGC-27	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELBTnpKSzVyPUO4MlM4OTFizszN	NUjQ[lBEW0GQR1XS
DOHH-2	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjkbphJUUN3ME2zPE44OTV6IN88US=>	MV\TRW5ITVJ?
KE-37	M3\UdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTN6Lkm4Nlgh\|ryP	MnrOV2FPT0WU
MOLT-13	NV;G[nZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTN7LkK1NFIh\|ryP	NH\rTJJUSU6JRWK=
ES1	MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTN7LkO4OUDPxE1?	Mn\IV2FPT0WU
SK-OV-3	NEf5VItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLMPFl5UUN3ME2zPU46PjR\|IN88US=>	Ml63V2FPT0WU
SNU-449	NVq4e3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTRyLkC3OlQh\|ryP	MnrQV2FPT0WU
KYSE-510	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTRyLkGyPVUh\|ryP	MmC5V2FPT0WU
HL-60	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjTcYZKSzVyPUSwMlk4QDNizszN	MVfTRW5ITVJ?
DJM-1	NIj3bo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33zdmlEPTB;NECuPVc6QSEQvF2=	Mm\HV2FPT0WU
TGBC11TKB	M3rSXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXrZ2lKSzVyPUSxMlA6OjZizszN	NUDJV3dtW0GQR1XS
U-2-OS	M2fUWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PGbWlEPTB;NEKuNlY1OSEQvF2=	Ml3XV2FPT0WU
NCI-H2030	NHv4OJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTR{LkSzOlgh\|ryP	M2LxfnNCVkeHUh?=
LU-135	NFzQd2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\UT3ZKSzVyPUSyMlU1PDdizszN	MmW5V2FPT0WU
ZR-75-30	MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXm[mNKSzVyPUSzMlA1QTNizszN	Moe3V2FPT0WU
GT3TKB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWXzUmhMUUN3ME20N{4zPjd7IN88US=>	NFXCV21USU6JRWK=
RPMI-2650	NWXoTlhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jKRWlEPTB;NEOuO\|gyPiEQvF2=	MlniV2FPT0WU
SAS	NVfvWJRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTR\|Lkm1N\|Qh\|ryP	M3vWd3NCVkeHUh?=
MDA-MB-231	NVLpcZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PlWmlEPTB;NEOuPVYxQSEQvF2=	Mn[wV2FPT0WU
JVM-3	M4faSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTR2LkC1N\|Mh\|ryP	NEnUS4RUSU6JRWK=
COLO-320-HSR	M1m2VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TmVGlEPTB;NESuOVY{OyEQvF2=	M{O2b3NCVkeHUh?=
SNB75	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYXTTm5DUUN3ME20OE43OTB3IN88US=>	NYXHb5RFW0GQR1XS
NCI-H441	NGjQT\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRTR2LkmzNlgh\|ryP	MWTTRW5ITVJ?
HCT-116	NXrod5RjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXjEZmpNUUN3ME20OE46QDZ6IN88US=>	NWGwflk6W0GQR1XS
NCI-H226	Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLmbZRKSzVyPUS1MlY{PjhizszN	MXLTRW5ITVJ?
CAL-33	NV3zRYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\6UGlEPTB;NEWuPVIyPyEQvF2=	NF3ud\|BUSU6JRWK=
NCI-H1437	MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DQXGlEPTB;NE[uN\|IyKM7:TR?=	MUfTRW5ITVJ?
HCC1187	M{HsUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rFVWlEPTB;NE[uOFI2PSEQvF2=	NIfJPIJUSU6JRWK=
NUGC-3	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHK0UZpKSzVyPUS2MlU4ODlizszN	MYTTRW5ITVJ?
T98G	NYTIPHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoLmTWM2OD12Nz61OFch\|ryP	MofrV2FPT0WU
OVCAR-8	M4XIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Py[2lEPTB;NEeuOlg{KM7:TR?=	NV25eppNW0GQR1XS
LB2241-RCC	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jYemlEPTB;NEeuO\|I4KM7:TR?=	MoPqV2FPT0WU
NCI-H358	M3nHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTR6LkGxOVIh\|ryP	NIL6UGlUSU6JRWK=
PANC-08-13	NXPzR5RET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7hNVhlUUN3ME20PE4yQDV\|IN88US=>	NHr4dlZUSU6JRWK=
KP-N-YN	NW\BU4hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVnLNVJ7UUN3ME20PE4zOTB{IN88US=>	NIewfnVUSU6JRWK=
NCI-H1755	NVHYOFBrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoDjTWM2OD12OD6yO\|I3KM7:TR?=	M3G4ZnNCVkeHUh?=
NCI-N87	NXTVNG5PT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUXJR\|UxRTR6LkK5PVEh\|ryP	MnHRV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo

Administration of PD173074 at 1 mg/kg/day or 2 mg/ka/day in mice can effectively block angiogenesis induced by either FGF or VEGF in a dose-dependent manner with no apparent toxicity. ^[1] PD173074 inhibits in vivo growth of mutant FGFR3-transfected NIH 3T3 cells in nude mice. Inhibition of FGFR3 by PD173074 delays tumor growth and increases survival of mice in a KMS11 xenograft myeloma model. ^[4] In the H-510 xenograft, oral aministration of PD173074 blocks tumor growth similar to that seen with single-agent cisplatin administration, increasing median survival compared with control sham-treated animals. In H-69 xenografts, PD173074 induces complete responses lasting >6 months in 50% of mice. These effects are correlated with increased apoptosis in excised tumors, but not a consequence of disrupted tumor vasculature. ^[5]

Protocol

Kinase Assay:^[1]	+ Expand In vitro kinase inhibition assays: Assays using the full-length FGFR-1 kinase are performed in a total volume of 100 μL containing 25 mM HEPES buffer (pH 7.4), 150 mM NaCl, 10 mM MnCl₂, 0.2 mM sodium orthovanadate, 750 μg/mL concentration of a random copolymer of glutamic acid and tyrosine (4:1), various concentrations of PD173074 and 60 to 75 ng of enzyme. The reaction is initiated by the addition of [γ-³²P]ATP (5 μM ATP containing 0.4 μCi of [γ-³²P]ATP per incubation), and samples are incubated at 25°C for 10 minutes. The reaction is terminated by the addition of 30% trichloroacetic acid and the precipitation of material onto glass-fiber filter mats. Filters are washed three times with 15% trichloroacetic acid, and the incorporation of [³²P] into the glutamate tyrosine polymer substrate is determined by counting the radioactivity retained on the filters in a Wallac 1250 betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples without enzyme. Specific activity is determined as total activity (enzyme plus buffer) minus nonspecific activity. The concentration of PD173074 that inhibits FGFR-1 enzymatic activity by 50% (IC50) is determined graphically.
Cell Research:^[4]	+ Expand Cell lines: KMS11 and KMS18 Concentrations: Dissolved in DMSO, final concentrations ~100 nM Incubation Time: 48 hours Method: Cells are incubated with increasing concentrations of PD173074 in the presence of aFGF/heparin for 48 hours. The percentage of viable cells is determined by MTT. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Swiss Webster mice with induced corneal angiogenesis Formulation: Prepared in sterile fashion Dosages: ~2 mg/kg/day Administration: Administered intraperitoneally (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	100 mg/mL (190.95 mM)
	Ethanol	100 mg/mL (190.95 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+corn oil For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD173074 SDF

Molecular Weight	523.67
Formula	C₂₈H₄₁N₇O₃
CAS No.	219580-11-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What is the half-life of PD173074(S1264) in vivo?
Answer:
According to literature research, PD173074 is given twice daily because it has a short half-life in vivo, please refer to the following link for detailed pharmacokinetic information (Supplementary Figure 8B): http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3990281/#!po=50.0000.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Pan FGFR Inhibitor

BGJ398 (NVP-BGJ398) : FGFR1/2/3-selective, IC50=0.9 nM/1.4 nM/1 nM.
Most Potent FGFR Inhibitor

AZD4547 : FGFR1, IC50=0.2 nM; FGFR2, IC50=2.5 nM; FGFR3, IC50=1.8 nM.
FDA-approved FGFR Inhibitor

Ponatinib (AP24534) : Approved by FDA for resistant or intolerant CML and Ph+ ALL.
Newest FGFR Inhibitor

SSR128129E ^New : Orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.

Related FGFR Products4

CH5183284 (Debio-1347) ^New

CH5183284 is a selective and orally available FGFR inhibitor with IC50 of 9.3 nM, 7.6 nM, 22 nM, and 290 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. Phase 1.
BLU9931 ^New

BLU9931 is a potent, selective, and irreversible FGFR4 inhibitor with IC50 of 3 nM, about 297-, 184-, and 50-fold selectivity over FGFR1/2/3, respectively.
PX-478 2HCl ^New

PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.
BGJ398 (NVP-BGJ398|Infigratinib)

BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
AZD4547

AZD4547 is a novel selective FGFR inhibitor targeting FGFR1/2/3 with IC50 of 0.2 nM/2.5 nM/1.8 nM in cell-free assays, weaker activity against FGFR4, VEGFR2(KDR), and little activity observed against IGFR, CDK2, and p38. Phase 2/3.

Features:Greater selectivity for FGFR1-3 over FGFR4. AZD4547 is active against the tyrosine kinase activity of both the wild-type and mutant forms of FGFR.
SSR128129E

SSR128129E is an orally-active and allosteric FGFR1 inhibitor with IC50 of 1.9 μM, while not affecting other related RTKs.
LY2874455

LY2874455 is a pan-FGFR inhibitor with IC50 of 2.8 nM, 2.6 nM, 6.4 nM, and 6 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively, and also inhibits VEGFR2 activity with IC50 of 7 nM. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.
Dasatinib

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PD173074

Cited by 27 Publications

7 Customer Reviews

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD173074 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products4

Choose Your Country or Region

By Signaling Pathways

By product type

PD173074

Cited by 27 Publications

7 Customer Reviews

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download PD173074 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Tech Support

Frequently Asked Questions

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)